|

Novel Therapy Target in Metastatic Prostate Cancer

RECRUITINGSponsored by Fudan University
Actively Recruiting
SponsorFudan University
Started2023-08-01
Est. completion2026-12-01
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05577689

Summary

The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

1. Histologically confirmed prostate cancer
2. metastatic disease confirmed by image examination
3. Patients who can undergo surgery or biopsy for prostate cancer
4. Able to provide informed consent

Exclusion Criteria:

1. Patients diagnosed with other types of cancer besides prostate cancer
2. Not accessible to surgery sample
3. Patients fail to provide informed consent
4. Other situation that researchers think are unsuitable for this study

Conditions2

CancerProstate Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.